This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Luminex Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Luminex Corporation has been struggling lately, but the selling pressure may be coming to an end soon
How Luminex (LMNX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Luminex (LMNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Surging Earnings Estimates Signal Good News for Luminex (LMNX)
by Zacks Equity Research
Luminex (LMNX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Zacks.com featured highlights include: Acacia, Virtu and Luminex
by Zacks Equity Research
Zacks.com featured highlights include: Acacia, Virtu and Luminex
3 Momentum Anomaly Stocks to Consider Amid Market Volatility
by Zacks Equity Research
These fast movers are witnessing a short-term pullback in price as the COVID-19 pandemic dents investors' optimism. So, this could essentially be a great entry point for garnering better returns.
New Strong Buy Stocks for May 7th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Luminex (LMNX) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Luminex's (LMNX) first-quarter earnings benefit from solid performance across Consumable Sales, Assay, Service and Other Revenues.
PerkinElmer (PKI) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results likely to reflect top-line growth and robust performance at Diagnostics segment. However, forex is likely to have remained a woe.
Should You Buy Luminex Corporation (LMNX) Ahead of Earnings?
by Payel Dhar
Luminex Corporation (LMNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
T2 Biosystems (TTOO) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
T2 Biosystems' (TTOO) first-quarter performance is likely to reflect growth in product revenues.